Cited 104 times in
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.